Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955874 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPK1SIGMAR1PYCR1NPSR1 | |
| Hydrochloric Acid SCHEMBL11711448 | 0.98 | ALDH1A1 (0.33) | ALDH1A1MAPK1SIGMAR1PYCR1NPSR1 | |
| SCHEMBL12126083 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MAPK1RAPGEF4ALOX15CYP2A6 | |
| SCHEMBL8147369 | 0.78 | CYP2A6 (0.42) | ALDH1A1MAPTMEN1KMT2ACYP2A6 | |
| SCHEMBL8150148 | 0.78 | CYP2A6 (0.42) | ALDH1A1MAPTMEN1KMT2ACYP2A6 | |
| SCHEMBL8499168 | 0.77 | ALDH1A1 (0.35) | ALDH1A1MAPK1SIGMAR1PYCR1NPSR1 | |
| SCHEMBL985929 | 0.76 | TDP1 (0.42) | ALDH1A1NPSR1RAPGEF4ALOX15MEN1 | |
| SCHEMBL29839690 | 0.76 | ALDH1A1 (0.42) | ALDH1A1CA1CA2 | |
| SCHEMBL8600425 | 0.76 | ALDH1A1 (0.42) | ALDH1A1CA1CA2 | |
| SCHEMBL29953658 | 0.76 | TDP1 (0.42) | ALDH1A1NPSR1RAPGEF4ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-9920044-B2 | Selective androgen receptor modulators | RADIUS PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-9750719-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9133182-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9115132-B2 | Tetrazole compounds as calcium channel blockers | Convergence Pharmaceuticals Limited (GB) | 2015-08-25 | — | — | US | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2590953-B1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited | 2013-08-15 | — | — | US | disclosed |
| EP-2590953-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004604-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Convergence Pharmaceuticals Limited (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322059-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, GPR119 | ALDH1A1 1277/4885MAPK1 1607/4885SIGMAR1 1755/4885 |
| US-20130210796-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | ALDH1A1 2584/4885MAPK1 3165/4885SIGMAR1 3130/4885 |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | ALDH1A1 2890/4885MAPK1 2743/4885SIGMAR1 364/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | ALDH1A1 2890/4885MAPK1 2743/4885SIGMAR1 364/4885 |
| US-20130217732-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | ALDH1A1 1277/4885MAPK1 1607/4885SIGMAR1 1755/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | ALDH1A1 272/4885MAPK1 1422/4885SIGMAR1 2554/4885 |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | ALDH1A1 1549/4885MAPK1 211/4885SIGMAR1 1324/4885 |
| US-20160015687-A1 | TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNB2 | ALDH1A1 2584/4885MAPK1 3165/4885SIGMAR1 3130/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | ALDH1A1 1246/4885MAPK1 1512/4885SIGMAR1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.